| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 12 | 2016 | 1346 | 1.870 |
Why?
|
| Stroke Volume | 6 | 2016 | 499 | 1.360 |
Why?
|
| Myocardial Infarction | 7 | 2009 | 402 | 1.130 |
Why?
|
| Antihypertensive Agents | 6 | 2011 | 261 | 1.080 |
Why?
|
| Anti-Arrhythmia Agents | 5 | 2012 | 66 | 0.990 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2012 | 108 | 0.940 |
Why?
|
| Hypertension | 6 | 2011 | 763 | 0.830 |
Why?
|
| Aspirin | 3 | 2008 | 163 | 0.820 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2009 | 67 | 0.810 |
Why?
|
| Acute Coronary Syndrome | 3 | 2013 | 35 | 0.780 |
Why?
|
| Hospitalization | 5 | 2016 | 927 | 0.740 |
Why?
|
| Heart Rate | 3 | 2012 | 502 | 0.620 |
Why?
|
| Ticlopidine | 2 | 2009 | 25 | 0.610 |
Why?
|
| Quality of Health Care | 3 | 2011 | 390 | 0.600 |
Why?
|
| Long QT Syndrome | 2 | 2008 | 36 | 0.590 |
Why?
|
| Humans | 66 | 2016 | 92337 | 0.590 |
Why?
|
| Postprandial Period | 2 | 2008 | 47 | 0.580 |
Why?
|
| Potassium | 2 | 2009 | 261 | 0.570 |
Why?
|
| Hospital Mortality | 3 | 2016 | 444 | 0.560 |
Why?
|
| Anticoagulants | 2 | 2013 | 443 | 0.550 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2009 | 159 | 0.550 |
Why?
|
| Hyperglycemia | 2 | 2008 | 176 | 0.530 |
Why?
|
| Coronary Vessels | 2 | 2009 | 197 | 0.520 |
Why?
|
| Heart | 2 | 2009 | 584 | 0.510 |
Why?
|
| Coronary Artery Disease | 4 | 2011 | 380 | 0.500 |
Why?
|
| Stents | 2 | 2009 | 417 | 0.490 |
Why?
|
| Secondary Prevention | 3 | 2013 | 172 | 0.480 |
Why?
|
| Length of Stay | 2 | 2016 | 798 | 0.450 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2016 | 201 | 0.440 |
Why?
|
| Sepsis | 2 | 2008 | 350 | 0.430 |
Why?
|
| Cardiovascular Diseases | 3 | 2009 | 743 | 0.420 |
Why?
|
| Atrial Fibrillation | 2 | 2008 | 377 | 0.420 |
Why?
|
| Amiodarone | 2 | 2008 | 14 | 0.360 |
Why?
|
| Medically Uninsured | 1 | 2011 | 64 | 0.360 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2011 | 60 | 0.360 |
Why?
|
| Ventricular Function, Left | 3 | 2010 | 638 | 0.360 |
Why?
|
| Tachycardia | 2 | 2012 | 36 | 0.360 |
Why?
|
| Vasopressins | 2 | 2001 | 50 | 0.350 |
Why?
|
| Oxytocin | 2 | 2001 | 74 | 0.330 |
Why?
|
| Coronary Disease | 2 | 2008 | 262 | 0.330 |
Why?
|
| Carotid Sinus | 1 | 2009 | 20 | 0.330 |
Why?
|
| Heart Failure, Systolic | 1 | 2009 | 6 | 0.330 |
Why?
|
| Pericardial Effusion | 1 | 2009 | 21 | 0.330 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2010 | 335 | 0.320 |
Why?
|
| Atenolol | 1 | 2009 | 26 | 0.320 |
Why?
|
| Aged | 17 | 2016 | 19943 | 0.320 |
Why?
|
| Blood Pressure | 5 | 2011 | 909 | 0.320 |
Why?
|
| Syncope | 1 | 2009 | 34 | 0.320 |
Why?
|
| Stroke | 6 | 2011 | 1038 | 0.320 |
Why?
|
| Electrocardiography | 2 | 2009 | 507 | 0.320 |
Why?
|
| Coronary Artery Bypass | 2 | 2008 | 245 | 0.320 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 34 | 0.310 |
Why?
|
| Scleroderma, Systemic | 1 | 2009 | 57 | 0.310 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 39 | 0.310 |
Why?
|
| Myocarditis | 1 | 2009 | 55 | 0.310 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 72 | 0.300 |
Why?
|
| Naproxen | 1 | 2008 | 15 | 0.300 |
Why?
|
| Prostaglandins | 1 | 2008 | 43 | 0.300 |
Why?
|
| Cause of Death | 1 | 2010 | 270 | 0.300 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2010 | 120 | 0.300 |
Why?
|
| Prognosis | 8 | 2012 | 3872 | 0.300 |
Why?
|
| Syncope, Vasovagal | 1 | 2008 | 4 | 0.300 |
Why?
|
| Propanolamines | 1 | 2008 | 18 | 0.300 |
Why?
|
| Ganglionectomy | 1 | 2008 | 2 | 0.300 |
Why?
|
| Hypoglycemia | 1 | 2009 | 110 | 0.300 |
Why?
|
| Propranolol | 1 | 2008 | 44 | 0.300 |
Why?
|
| Fingers | 1 | 2008 | 70 | 0.290 |
Why?
|
| Myoglobin | 1 | 2008 | 29 | 0.290 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2008 | 11 | 0.290 |
Why?
|
| Endarterectomy, Carotid | 1 | 2008 | 74 | 0.290 |
Why?
|
| Inpatients | 1 | 2011 | 331 | 0.290 |
Why?
|
| Creatine Kinase | 1 | 2008 | 53 | 0.290 |
Why?
|
| Atherosclerosis | 2 | 2008 | 262 | 0.290 |
Why?
|
| Troponin I | 1 | 2008 | 27 | 0.290 |
Why?
|
| Clostridium perfringens | 1 | 2007 | 8 | 0.290 |
Why?
|
| Medicare | 1 | 2011 | 440 | 0.290 |
Why?
|
| Vascular Malformations | 1 | 2008 | 19 | 0.290 |
Why?
|
| Umbilicus | 1 | 2007 | 5 | 0.290 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 6916 | 0.290 |
Why?
|
| Atrioventricular Node | 1 | 2008 | 35 | 0.290 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 46 | 0.290 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2007 | 9 | 0.290 |
Why?
|
| Radiation Injuries | 1 | 2009 | 158 | 0.280 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 75 | 0.280 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2008 | 43 | 0.280 |
Why?
|
| Coronary Vasospasm | 1 | 2007 | 8 | 0.280 |
Why?
|
| Echocardiography | 2 | 2010 | 968 | 0.280 |
Why?
|
| Hypertriglyceridemia | 1 | 2008 | 69 | 0.280 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 95 | 0.280 |
Why?
|
| Dyslipidemias | 1 | 2009 | 107 | 0.280 |
Why?
|
| Natriuretic Agents | 1 | 2007 | 2 | 0.280 |
Why?
|
| Carotid Stenosis | 1 | 2008 | 116 | 0.280 |
Why?
|
| Hyperlipidemias | 1 | 2008 | 92 | 0.280 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2010 | 227 | 0.280 |
Why?
|
| Aortic Valve Stenosis | 1 | 2009 | 157 | 0.280 |
Why?
|
| Cocaine | 1 | 2008 | 77 | 0.270 |
Why?
|
| Risk Assessment | 6 | 2010 | 2369 | 0.270 |
Why?
|
| Female | 24 | 2016 | 47893 | 0.270 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2007 | 55 | 0.270 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 328 | 0.270 |
Why?
|
| Defibrillators, Implantable | 1 | 2009 | 148 | 0.270 |
Why?
|
| Pulmonary Veins | 1 | 2008 | 93 | 0.270 |
Why?
|
| Clostridium Infections | 2 | 2014 | 125 | 0.270 |
Why?
|
| Male | 23 | 2016 | 43925 | 0.270 |
Why?
|
| Bretylium Compounds | 1 | 2006 | 1 | 0.270 |
Why?
|
| Ischemia | 1 | 2008 | 254 | 0.260 |
Why?
|
| Clindamycin | 1 | 2006 | 15 | 0.260 |
Why?
|
| Mitral Valve | 1 | 2009 | 275 | 0.260 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2006 | 18 | 0.260 |
Why?
|
| Diuretics | 1 | 2007 | 78 | 0.260 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 246 | 0.260 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2009 | 205 | 0.260 |
Why?
|
| Critical Illness | 1 | 2009 | 328 | 0.260 |
Why?
|
| Cardiotonic Agents | 1 | 2007 | 92 | 0.260 |
Why?
|
| Drug Eruptions | 1 | 2006 | 31 | 0.260 |
Why?
|
| Vasodilator Agents | 1 | 2007 | 145 | 0.260 |
Why?
|
| Referral and Consultation | 1 | 2009 | 353 | 0.260 |
Why?
|
| Drug Therapy, Combination | 4 | 2009 | 807 | 0.260 |
Why?
|
| Ventricular Fibrillation | 1 | 2006 | 69 | 0.260 |
Why?
|
| Body Mass Index | 1 | 2010 | 800 | 0.250 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 186 | 0.250 |
Why?
|
| Prenatal Diagnosis | 1 | 2006 | 110 | 0.250 |
Why?
|
| Critical Care | 1 | 2009 | 399 | 0.250 |
Why?
|
| Adenosine Triphosphate | 3 | 2001 | 319 | 0.250 |
Why?
|
| Thrombolytic Therapy | 1 | 2008 | 251 | 0.240 |
Why?
|
| Melanoma | 1 | 2009 | 482 | 0.240 |
Why?
|
| Patient Selection | 1 | 2009 | 689 | 0.240 |
Why?
|
| Blood Glucose | 1 | 2009 | 855 | 0.240 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 361 | 0.240 |
Why?
|
| Supraoptic Nucleus | 2 | 2001 | 2 | 0.230 |
Why?
|
| Stomach Neoplasms | 1 | 2007 | 297 | 0.230 |
Why?
|
| Neuropeptide Y | 2 | 2001 | 32 | 0.220 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 760 | 0.220 |
Why?
|
| Hypertension, Pulmonary | 1 | 2008 | 376 | 0.220 |
Why?
|
| Middle Aged | 16 | 2016 | 27030 | 0.220 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 213 | 0.220 |
Why?
|
| Substance P | 2 | 2001 | 62 | 0.220 |
Why?
|
| Heart Arrest | 1 | 2007 | 283 | 0.220 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2001 | 81 | 0.220 |
Why?
|
| Pregnancy Complications | 1 | 2006 | 346 | 0.210 |
Why?
|
| Psoriasis | 1 | 2006 | 247 | 0.210 |
Why?
|
| Epidermal Cyst | 1 | 2003 | 6 | 0.210 |
Why?
|
| Meningitis, Aseptic | 1 | 2003 | 8 | 0.210 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2008 | 492 | 0.210 |
Why?
|
| Obesity | 1 | 2010 | 1016 | 0.200 |
Why?
|
| Spinal Neoplasms | 1 | 2003 | 78 | 0.190 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2001 | 3 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2010 | 887 | 0.190 |
Why?
|
| Decision Making | 1 | 2007 | 680 | 0.190 |
Why?
|
| Diagnosis, Differential | 5 | 2014 | 1592 | 0.180 |
Why?
|
| Risk Factors | 8 | 2015 | 5704 | 0.180 |
Why?
|
| Hydrocortisone | 1 | 2003 | 304 | 0.180 |
Why?
|
| Neuropeptides | 1 | 2001 | 114 | 0.180 |
Why?
|
| Purinergic Agonists | 1 | 2000 | 1 | 0.180 |
Why?
|
| Adrenergic Agonists | 1 | 2000 | 2 | 0.180 |
Why?
|
| Pyridoxal Phosphate | 1 | 2000 | 12 | 0.180 |
Why?
|
| Neurotransmitter Agents | 1 | 2001 | 108 | 0.180 |
Why?
|
| Incidence | 3 | 2011 | 1661 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 810 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 1191 | 0.170 |
Why?
|
| Survival Rate | 3 | 2009 | 1927 | 0.160 |
Why?
|
| HIV Infections | 1 | 2009 | 895 | 0.160 |
Why?
|
| Confidence Intervals | 2 | 2010 | 219 | 0.160 |
Why?
|
| Brain Ischemia | 2 | 2015 | 405 | 0.160 |
Why?
|
| Risk | 3 | 2010 | 661 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2011 | 8740 | 0.150 |
Why?
|
| Drug Interactions | 2 | 2009 | 245 | 0.150 |
Why?
|
| Contraindications | 2 | 2009 | 70 | 0.150 |
Why?
|
| Severity of Illness Index | 3 | 2010 | 1919 | 0.150 |
Why?
|
| Systole | 2 | 2008 | 115 | 0.140 |
Why?
|
| Fatal Outcome | 2 | 2009 | 299 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 866 | 0.140 |
Why?
|
| Postoperative Complications | 1 | 2008 | 2458 | 0.140 |
Why?
|
| Phenylephrine | 3 | 2001 | 36 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2010 | 1511 | 0.140 |
Why?
|
| Reference Values | 2 | 2008 | 660 | 0.130 |
Why?
|
| Ultrasonography | 2 | 2009 | 708 | 0.130 |
Why?
|
| Precipitating Factors | 1 | 2016 | 5 | 0.130 |
Why?
|
| Norepinephrine | 3 | 2001 | 173 | 0.130 |
Why?
|
| Adult | 7 | 2009 | 27532 | 0.130 |
Why?
|
| Diarrhea | 2 | 2014 | 180 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3509 | 0.120 |
Why?
|
| Weight Gain | 1 | 2016 | 124 | 0.120 |
Why?
|
| Brain Infarction | 1 | 2015 | 23 | 0.120 |
Why?
|
| Pellagra | 1 | 2014 | 2 | 0.120 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 39 | 0.110 |
Why?
|
| Dermatitis | 1 | 2014 | 35 | 0.110 |
Why?
|
| Pneumonia | 1 | 2016 | 189 | 0.110 |
Why?
|
| Medication Adherence | 1 | 2016 | 147 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2011 | 2978 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 2016 | 322 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 1939 | 0.100 |
Why?
|
| Accidental Falls | 2 | 2011 | 49 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 989 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2011 | 4468 | 0.100 |
Why?
|
| Dementia | 1 | 2014 | 203 | 0.100 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 217 | 0.100 |
Why?
|
| Hypotension, Orthostatic | 1 | 2011 | 4 | 0.100 |
Why?
|
| Benzazepines | 1 | 2012 | 65 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1733 | 0.090 |
Why?
|
| Angina Pectoris | 2 | 2008 | 29 | 0.090 |
Why?
|
| Time Factors | 3 | 2010 | 5430 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2010 | 694 | 0.090 |
Why?
|
| Comorbidity | 2 | 2011 | 987 | 0.090 |
Why?
|
| Drug Synergism | 2 | 2001 | 312 | 0.080 |
Why?
|
| United States | 3 | 2011 | 7348 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2010 | 89 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 58 | 0.080 |
Why?
|
| Cardiac Tamponade | 1 | 2009 | 23 | 0.080 |
Why?
|
| Edema | 1 | 2009 | 68 | 0.080 |
Why?
|
| Atrioventricular Block | 1 | 2009 | 26 | 0.080 |
Why?
|
| Logistic Models | 2 | 2011 | 1239 | 0.080 |
Why?
|
| Vipoma | 1 | 2009 | 4 | 0.080 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2009 | 15 | 0.080 |
Why?
|
| California | 1 | 2009 | 156 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2009 | 289 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2009 | 103 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2010 | 173 | 0.080 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2008 | 6 | 0.080 |
Why?
|
| Mediastinal Neoplasms | 1 | 2009 | 45 | 0.080 |
Why?
|
| Probability | 1 | 2010 | 357 | 0.080 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2009 | 54 | 0.080 |
Why?
|
| HIV | 1 | 2009 | 48 | 0.080 |
Why?
|
| Echocardiography, Doppler | 1 | 2010 | 193 | 0.080 |
Why?
|
| Metoprolol | 1 | 2008 | 15 | 0.080 |
Why?
|
| Tilt-Table Test | 1 | 2008 | 4 | 0.080 |
Why?
|
| Chylomicron Remnants | 1 | 2008 | 2 | 0.080 |
Why?
|
| Prosthesis Design | 1 | 2009 | 303 | 0.080 |
Why?
|
| Platelet Activation | 1 | 2008 | 16 | 0.070 |
Why?
|
| Glipizide | 1 | 2008 | 2 | 0.070 |
Why?
|
| Cyclohexanes | 1 | 2008 | 8 | 0.070 |
Why?
|
| Age Factors | 2 | 2010 | 1905 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2009 | 126 | 0.070 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 46 | 0.070 |
Why?
|
| Blood Platelets | 1 | 2008 | 148 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 158 | 0.070 |
Why?
|
| Ventricular Premature Complexes | 1 | 2008 | 8 | 0.070 |
Why?
|
| Fibrosis | 1 | 2009 | 239 | 0.070 |
Why?
|
| Carbamates | 1 | 2008 | 16 | 0.070 |
Why?
|
| Phenylalanine | 1 | 2008 | 36 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2001 | 1235 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2008 | 235 | 0.070 |
Why?
|
| Sulfonylurea Compounds | 1 | 2008 | 67 | 0.070 |
Why?
|
| Hemolysis | 1 | 2007 | 62 | 0.070 |
Why?
|
| Blood Transfusion | 1 | 2008 | 168 | 0.070 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 36 | 0.070 |
Why?
|
| ROC Curve | 1 | 2010 | 785 | 0.070 |
Why?
|
| Acute Disease | 1 | 2009 | 856 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 871 | 0.070 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2009 | 190 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2008 | 120 | 0.070 |
Why?
|
| Pacemaker, Artificial | 1 | 2008 | 97 | 0.070 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2008 | 84 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2008 | 673 | 0.070 |
Why?
|
| Exercise Test | 1 | 2008 | 171 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2009 | 324 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 868 | 0.070 |
Why?
|
| Piperidines | 1 | 2008 | 164 | 0.070 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2006 | 69 | 0.070 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 237 | 0.070 |
Why?
|
| Registries | 1 | 2011 | 902 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2010 | 393 | 0.060 |
Why?
|
| Catheterization, Peripheral | 1 | 2006 | 62 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2007 | 168 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2006 | 241 | 0.060 |
Why?
|
| Reoperation | 1 | 2008 | 654 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2009 | 429 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 449 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2008 | 377 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 233 | 0.060 |
Why?
|
| Thrombosis | 1 | 2008 | 312 | 0.060 |
Why?
|
| Cross Infection | 1 | 2006 | 153 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2007 | 453 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 391 | 0.060 |
Why?
|
| Rats | 2 | 2001 | 4067 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2008 | 3775 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1902 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 608 | 0.050 |
Why?
|
| Injections, Spinal | 1 | 2003 | 47 | 0.050 |
Why?
|
| Recurrence | 1 | 2006 | 1180 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 2003 | 61 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2009 | 774 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 694 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 1150 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 767 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 359 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 2680 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1399 | 0.050 |
Why?
|
| Biomarkers | 1 | 2008 | 1850 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2006 | 795 | 0.040 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2000 | 3 | 0.040 |
Why?
|
| Purinergic P2 Receptor Antagonists | 1 | 2000 | 4 | 0.040 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2000 | 4 | 0.040 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 33 | 0.040 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2000 | 16 | 0.040 |
Why?
|
| Maleimides | 1 | 2000 | 26 | 0.040 |
Why?
|
| Culture Techniques | 1 | 2000 | 89 | 0.040 |
Why?
|
| Pain | 2 | 2014 | 406 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2001 | 3508 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 291 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2000 | 268 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 1212 | 0.040 |
Why?
|
| Pregnancy | 1 | 2006 | 3110 | 0.040 |
Why?
|
| Indoles | 1 | 2000 | 306 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2001 | 756 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 652 | 0.040 |
Why?
|
| Animals | 3 | 2001 | 28003 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2001 | 2902 | 0.030 |
Why?
|
| Paresthesia | 1 | 2014 | 16 | 0.030 |
Why?
|
| Polysomnography | 1 | 2015 | 151 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 89 | 0.030 |
Why?
|
| Neurons | 1 | 2001 | 1596 | 0.030 |
Why?
|
| Hepatitis C | 1 | 2014 | 179 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 106 | 0.020 |
Why?
|
| Veterans | 1 | 2011 | 89 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2010 | 22 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2010 | 34 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 376 | 0.020 |
Why?
|
| Indium Radioisotopes | 1 | 2009 | 10 | 0.020 |
Why?
|
| Hypokalemia | 1 | 2009 | 23 | 0.020 |
Why?
|
| Octreotide | 1 | 2009 | 28 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 217 | 0.020 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2009 | 46 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2009 | 149 | 0.020 |
Why?
|
| Monokines | 1 | 2007 | 3 | 0.020 |
Why?
|
| Arteritis | 1 | 2007 | 9 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2007 | 26 | 0.020 |
Why?
|
| Lymphokines | 1 | 2007 | 75 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 126 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2007 | 111 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 2352 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 1228 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 843 | 0.010 |
Why?
|